The results presented in this systematic review and meta-analysis contribute to refining the knowledge about the relevance of IL-33 in individuals with obesity and T2D, guiding future research and enriching the broader discourse on therapeutic targets for metabolic disorders. The gene discussed is IL33; the disease is type 2 diabetes mellitus.